Effect of a satiating meal on the concentrations of procolipase propeptide in the serum and urine of normal and morbidly obese subjects.
The effect of a satiating meal on the serum and urinary concentrations of procolipase propeptide (Ala-Pro-Gly-Pro-Arg, APGPR) immunoreactivity, as measured by enzyme linked immunosorbent assay (ELISA) specific for free APGPR, has been studied in normal and morbidly obese human subjects. The normal subjects displayed a biphasic response with coordinate increases in both serum and urine APGPR immunoreactivity both occurring within the first two hours after the meal. In two of three of the morbidly obese subjects, this early rise in APGPR concentration in urine was not seen but was followed by a slow rise in urinary APGPR immunoreactivity at four to six hours. In both the normal and obese groups, the urinary immunoreactive signal was found to coelute with synthetic APGPR on gel chromatography. In rats, procolipase propeptide (Val-Pro-Asp-Pro-Arg, VPDPR) specifically inhibits fat intake early in the postprandial period when given peripherally or centrally. This study suggests that in humans APGPR reaches the circulation shortly after feeding and is excreted in the urine. These findings are consistent with the hypothesis that human procolipase propeptide may also act as a satiety signal. In addition the late appearance of the peptide in some of the morbidly obese patients could be associated with perturbation of appetite control in these subjects.
Bowyer
R C
RC
Department of Surgery, St George's Hospital Medical School, London.
Rowston
W M
WM
Jehanli
A M
AM
Lacey
J H
JH
Hermon-Taylor
J
J
D000328:Adult; D003089:Colipases / Q000097:blood / Q000378:metabolism* / Q000652:urine; D005260:Female; D005502:Food; D006801:Humans; D008297:Male; D009767:Obesity, Morbid / Q000097:blood / Q000378:metabolism* / Q000652:urine; D009842:Oligopeptides / Q000097:blood / Q000378:metabolism* / Q000652:urine
D003089:Colipases; D009842:Oligopeptides; C072711:procolipase activation peptide